Atea Pharmaceuticals Inc [AVIR] stock prices are up 5.05% to $3.12 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AVIR shares have gain 4.00% over the last week, with a monthly amount drifted -11.36%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Atea Pharmaceuticals Inc [NASDAQ: AVIR] stock has seen the most recent analyst activity on August 13, 2024, when Morgan Stanley upgraded its rating to a Equal-Weight and also boosted its price target to $6.88 from $2. Previously, JP Morgan downgraded its rating to Underweight on August 10, 2023. On January 06, 2022, downgrade downgraded it’s rating to Underweight and revised its price target to $7 on the stock. SVB Leerink downgraded its rating to a Mkt Perform. JP Morgan downgraded its rating to a Neutral and reduced its price target to $16 on October 20, 2021. Morgan Stanley downgraded its rating to Equal-Weight for this stock on October 05, 2021, but kept the price target unchanged to $55. In a note dated November 25, 2020, Evercore ISI initiated an Outperform rating.
The stock price of Atea Pharmaceuticals Inc [AVIR] has been fluctuating between $2.75 and $4.60 over the past year. Currently, Wall Street analysts expect the stock to reach $6.88 within the next 12 months. Atea Pharmaceuticals Inc [NASDAQ: AVIR] shares were valued at $3.12 at the most recent close of the market. An investor can expect a potential return of 120.51% based on the average AVIR price forecast.
Analyzing the AVIR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is -0.35 and Total Capital is -0.43. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.99 points at the first support level, and at 2.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.21, and for the 2nd resistance point, it is at 3.29.
Ratios To Look Out For
It’s worth pointing out that Atea Pharmaceuticals Inc [NASDAQ:AVIR]’s Current Ratio is 19.33. Also, the Quick Ratio is 19.33, while the Cash Ratio stands at 3.91.
Transactions by insiders
Recent insider trading involved BERGER FRANKLIN M, Director, that happened on Dec 10 ’24 when 0.36 million shares were sold. Lead Independent Director, Franklin Berger completed a deal on Dec 10 ’24 to buy 0.36 million shares. Meanwhile, President, CEO, and Chairman Sommadossi Jean-Pierre sold 33941.0 shares on Sep 17 ’24.
